
    
      This trial is an open, dose escalation phase I clinical trial study of patients with advanced
      cancer who have failed standard treatment. The trial is divided into a dose escalation phase
      and an expansion phase.

      Approximately 130 patients will be enrolled in this trial. The dose-increasing phase is about
      30 cases, and the expansion stage is about 100 cases.
    
  